論文・技術情報追加のお知らせ

1. The association of hypophysitis with immune checkpoint inhibitors use: Gaining insight through the FDA pharmacovigilance database.

免疫チェックポイント阻害薬と副作用の関連性を調査し、脳下垂体炎のシグナルを検出

対象DB：FAERS

2. Reports of COVID-19 Vaccine Adverse Events in Predominantly Republican vs Democratic States.

保守派州ではCOVID-19ワクチン副作用の報告が多い

対象DB：FAERS,VAERS

3. Post-marketing safety evaluation of lurbinectedin: a pharmacovigilance analysis based on the FAERS database.

2020年6月以降、FAERSでのルルビネクテジンの有害事象を評価

対象DB：FAERS

4. Gastrointestinal infections and gastrointestinal haemorrhage are underestimated but serious adverse events in chimeric antigen receptor T-cell recipients: A real-world study.

CAR-T療法に関連する消化器系の有害事象を解析

対象DB：FAERS

5. Real-World Safety Data of the Orphan Drug Onasemnogene Abeparvovec (Zolgensma((R))) for the SMA Rare Disease: A Pharmacovigilance Study Based on the EMA Adverse Event Reporting System.

ゾルゲンスマの安全性を調査、レポート増加

対象DB：FAERS

6. The Association between Molecular Initiating Events and Drug-Induced Hiccups.

薬物誘発性ヒッコウのメカニズムを解明

対象DB：FAERS

7. Serious Safety Signals and Prediction Features Following COVID-19 mRNA Vaccines Using the Vaccine Adverse Event Reporting System.

COVID-19ワクチン接種後の重篤な副反応の予測に関する研究

対象DB：FAERS,KAERS,VAERS

8. Safety of Dual Orexin Receptor Antagonist Daridorexant: A Disproportionality Analysis of Publicly Available FAERS Data.

ダリドレキサントの安全性に関する実世界データ

対象DB：FAERS

9. VAERS Vasculitis Adverse Events Retrospective Study: Etiology Model of Immune Complexes Activating Fc Receptors in Kawasaki Disease and Multisystem Inflammatory Syndromes.

ワクチンと血管炎の関連性を検証

対象DB：FAERS,VAERS

10. Real-world safety of Levetiracetam: Mining and analysis of its adverse drug reactions based on FAERS database.

レベチラセタムの安全性プロファイルの解析

対象DB：FAERS

11. A real-world disproportionality analysis of Everolimus: data mining of the public version of FDA adverse event reporting system.

FAERSデータを用いたエベロリムスの有害事象解析

対象DB：FAERS

12. Novel insights into post-marketing adverse events associated with lenvatinib: A comprehensive analysis utilizing the FAERS database.

レンバチニブ関連の有害事象の継続的な監視と特定

対象DB：FAERS

13. Adverse Reactions to Evolocumab: Analysis of Real-World Data from EudraVigilance.

EudraVigilanceデータからのエボロクマブの安全性解析

対象DB：EudraVigilance

14. Nivolumab Safety in Renal Cell Carcinoma: A Case Report.

ニボルマブの副作用による治療中止のケース

対象DB：EudraVigilance

15. Investigating the safety profiles of exogenous melatonin and associated adverse events: A pharmacovigilance study using WHO-VigiBase.

メラトニンの安全性に関するファーマコビジランス研究

対象DB：VigiBase

16. Clinical Efficacy of Beta-1 Selective Beta-Blockers Versus Propranolol in Patients With Thyroid Storm: A Retrospective Cohort Study.

甲状腺ストーム治療におけるβ遮断薬の選択と入院死亡率の関連を検討

対象DB：DPC

17. Potassium Iodide Use and Patient Outcomes for Thyroid Storm: An Observational Study.

甲状腺ストーム患者において、KI使用は入院死亡率の低下と関連する可能性

対象DB：DPC

18. Comparable Psychotropic Prescription Rates After Hospital Discharge Between Patients with COVID-19 and Those With Non-COVID-19-Related Respiratory Infection.

COVID-19患者の精神症状は重症化と関連

対象DB：DPC

19. Effectiveness of antibiotic therapy for early recurrence of peritonsillar cellulitis and abscesses: A retrospective cohort study.

扁桃周囲炎において早期の経口抗生物質切り替え療法が有効

対象DB：DPC

20. Effects of long-term HbA1c variability on serious infection risks in patients with type 2 diabetes and the influence of age, sex and ethnicity: A cohort study of primary care data.

糖尿病患者のHbA1c変動と重篤な感染の関連を探索

対象DB：CPRD

21. Burden of Disease and Treatment Patterns Amongst Patients With Vitiligo: Findings From a National, Longitudinal Retrospective Study in the United Kingdom.

白斑の有病率は増加し、メンタルヘルスの合併症が多く、早期治療の必要性

対象DB：CPRD

22. Ethnic differences in depression and anxiety among adults with atopic eczema: Population-based matched cohort studies within UK primary care.

アトピー性皮膚炎とうつ病、不安の関連は、人種によって異なることが示唆

対象DB：CPRD

23. Sodium-glucose cotransporter-2 inhibitors and the risk of atrial fibrillation in patients with type 2 diabetes: a population-based cohort study.

SGLT2阻害剤は2型糖尿病患者において、他の血糖降下薬と比較して心房細動のリスクを低減する可能性

対象DB：CPRD

24. Determining prescriptions in electronic healthcare record data: methods for development of standardized, reproducible drug codelists.

薬剤コードリストの作成方法を標準化し、再現性を確保するための手法が開発

対象DB：CPRD